AU2022242476A1 - Use of heterocyclic compound in treating diseases related to kinase drug-resistant mutation and method therefor - Google Patents
Use of heterocyclic compound in treating diseases related to kinase drug-resistant mutation and method therefor Download PDFInfo
- Publication number
- AU2022242476A1 AU2022242476A1 AU2022242476A AU2022242476A AU2022242476A1 AU 2022242476 A1 AU2022242476 A1 AU 2022242476A1 AU 2022242476 A AU2022242476 A AU 2022242476A AU 2022242476 A AU2022242476 A AU 2022242476A AU 2022242476 A1 AU2022242476 A1 AU 2022242476A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- group
- ret
- drug
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110316525 | 2021-03-24 | ||
| CN202110316525.6 | 2021-03-24 | ||
| CN2022074619 | 2022-01-28 | ||
| CN202210109766 | 2022-01-28 | ||
| CNPCT/CN2022/074619 | 2022-01-28 | ||
| CN202210109766.8 | 2022-01-28 | ||
| PCT/CN2022/081890 WO2022199503A1 (zh) | 2021-03-24 | 2022-03-21 | 杂环化合物治疗与激酶耐药突变相关的疾病的用途和方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022242476A1 true AU2022242476A1 (en) | 2023-10-26 |
Family
ID=83396096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022242476A Pending AU2022242476A1 (en) | 2021-03-24 | 2022-03-21 | Use of heterocyclic compound in treating diseases related to kinase drug-resistant mutation and method therefor |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250268897A1 (https=) |
| EP (1) | EP4316490A4 (https=) |
| JP (1) | JP2024511389A (https=) |
| KR (1) | KR20230159367A (https=) |
| CN (1) | CN116801882A (https=) |
| AU (1) | AU2022242476A1 (https=) |
| WO (1) | WO2022199503A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022022398A1 (zh) * | 2020-07-28 | 2022-02-03 | 四川科伦博泰生物医药股份有限公司 | 一种嘧啶类化合物的盐和晶型及其制备方法 |
| CN120897743A (zh) | 2023-05-19 | 2025-11-04 | 四川科伦博泰生物医药股份有限公司 | 杂环化合物治疗与ret基因改变相关疾病的用途和方法 |
| WO2026017002A1 (zh) * | 2024-07-16 | 2026-01-22 | 四川科伦博泰生物医药股份有限公司 | 以杂环化合物为活性成分的药物组合物、其制备方法及用途 |
| GB202410599D0 (en) | 2024-07-19 | 2024-09-04 | Ellipses Pharma Ltd | Therapeutics useful synergistic combinations |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9145391B2 (en) * | 2011-05-10 | 2015-09-29 | Merck Sharp & Dohme Corp. | Bipyridylaminopyridines as Syk inhibitors |
| US10227329B2 (en) * | 2016-07-22 | 2019-03-12 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| TWI791053B (zh) * | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| JP7060694B2 (ja) * | 2018-01-18 | 2022-04-26 | アレイ バイオファーマ インコーポレイテッド | Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物 |
| JP7615056B2 (ja) | 2019-02-19 | 2025-01-16 | スーチュアン・コールン－バイオテック・バイオファーマシューティカル・カンパニー・リミテッド | 複素環化合物、これを含む薬物組成物、その製造方法および使用 |
| EA202193049A1 (ru) * | 2019-05-21 | 2022-02-14 | Вороной Инк. | N-содержащее производное гетероарила и фармацевтическая композиция, содержащая его в качестве активного ингредиента для предупреждения или лечения рака |
| JP7732668B2 (ja) * | 2019-08-05 | 2025-09-02 | 北京志健金瑞生物医▲薬▼科技有限公司 | 窒素含有多環式縮合環系化合物、その薬学的組成物、製造方法及び用途 |
-
2022
- 2022-03-21 KR KR1020237025273A patent/KR20230159367A/ko active Pending
- 2022-03-21 JP JP2023557142A patent/JP2024511389A/ja active Pending
- 2022-03-21 AU AU2022242476A patent/AU2022242476A1/en active Pending
- 2022-03-21 US US18/283,673 patent/US20250268897A1/en active Pending
- 2022-03-21 WO PCT/CN2022/081890 patent/WO2022199503A1/zh not_active Ceased
- 2022-03-21 EP EP22774164.2A patent/EP4316490A4/en active Pending
- 2022-03-21 CN CN202280011390.5A patent/CN116801882A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250268897A1 (en) | 2025-08-28 |
| EP4316490A4 (en) | 2025-03-05 |
| EP4316490A1 (en) | 2024-02-07 |
| KR20230159367A (ko) | 2023-11-21 |
| WO2022199503A1 (zh) | 2022-09-29 |
| JP2024511389A (ja) | 2024-03-13 |
| CN116801882A (zh) | 2023-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4316490A1 (en) | Use of heterocyclic compound in treating diseases related to kinase drug-resistant mutation and method therefor | |
| RU2563644C2 (ru) | Пирролопиримидиновые соединения и их применения | |
| JP2022541127A (ja) | キナーゼ阻害剤としての置換された縮合複素芳香族二環式化合物およびその使用 | |
| JP7821259B2 (ja) | 複素環化合物、これを含む薬物組成物、その製造方法および使用 | |
| KR102111570B1 (ko) | 신규 이미다조피리다진 화합물 및 그의 용도 | |
| WO2018066718A1 (en) | Therapeutic compounds | |
| CN111484479B (zh) | 氮杂环化合物、包含其的药物组合物及其制备方法和用途 | |
| TWI891753B (zh) | 醯胺類化合物及其用途 | |
| EP2935272A1 (en) | Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors | |
| WO2019085894A1 (zh) | 一类含氮稠环化合物及其制备方法和用途 | |
| KR20260014519A (ko) | Ret 유전자 변화와 관련된 질병을 치료하기 위한 헤테로사이클릭 화합물의 용도 및 이를 위한 방법 | |
| CN119301101A (zh) | 甲基吡唑化合物、包含其的药物组合物及其制备方法和用途 | |
| CA3210109A1 (en) | Use of heterocyclic compound in treating diseases related to kinase drug-resistant mutation and method therefor | |
| CN116323582B (zh) | 杂芳环类化合物及其用途 | |
| CN117126140A (zh) | 具有蛋白激酶抑制活性的杂环化合物、包含其的药物组合物及其制备方法和用途 | |
| EP4556478A1 (en) | Tgf-beta inhibitor compound and use thereof | |
| CN116903626A (zh) | 芳基酰胺化合物、包含其的药物组合物及其制备方法和用途 | |
| HK40095637A (zh) | 杂芳环类化合物及其用途 | |
| AU2024323272A1 (en) | Jak inhibitor compound and use thereof | |
| CN121824539A (zh) | 稠环化合物及其制备方法和应用 | |
| HK40095637B (zh) | 杂芳环类化合物及其用途 | |
| HK40029610B (zh) | 一种哒嗪类衍生物抑制剂、其制备方法和应用 | |
| HK1157569A1 (en) | Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine h 4 receptor |